Loading...
•
Mar 31, 2020
Zentalis Q1 2020 Earnings Report
Zentalis reported financial results for the first quarter ended March 31, 2020, and highlighted recent corporate accomplishments.
Key Takeaways
Zentalis Pharmaceuticals reported a net loss of $16.2 million for Q1 2020, compared to a net loss of $8.7 million for the same period in 2019. The company's cash and cash equivalents were $63.7 million as of March 31, 2020. They completed an initial public offering, raising approximately $190.0 million in gross proceeds.
Completed initial public offering, raising approximately $190.0 million in gross proceeds.
FDA cleared the Company’s IND application for ZN-d5, an investigational oral selective inhibitor of B-cell lymphoma 2 (BCL-2).
Cash and cash equivalents totaled $63.7 million as of March 31, 2020.
Net loss for the first quarter of 2020 was $16.2 million.
Forward Guidance
Company expects that its existing cash and cash equivalents, together with the net proceeds from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...